Igg4 related disease
Drug research and approvals for igg4 related disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 22 studies of igg4 related disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.
- Recruiting worldwide: 22
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 22 recruiting on ClinicalTrials.gov ↗- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric…NCT07222553 · Phase 2 · Amgen · starts Oct 21, 2026
- Validation of the Odesa Criteria 2026 for Autoimmune PancreatitisNCT07536841 · Not reported · Military Medical Clinical Center of the Southern Region, Ukraine · starts May 1, 2026
- Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseNCT07061938 · Phase 1 / Phase 2 · Acepodia Biotech, Inc. · starts Jan 1, 2026
- Dermal Priming in Enhancing Vaccine ImmunogenicityNCT07925996 · Not applicable · Cambridge University Hospitals NHS Foundation Trust · starts Dec 15, 2025
- A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseaseNCT07190196 · Phase 3 · Sanofi · starts Sep 26, 2025
- The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and…NCT07535554 · Phase 2 / Phase 3 · Universitaire Ziekenhuizen KU Leuven · starts Sep 17, 2025
- Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related DiseaseNCT07148791 · Phase 2 · Chinese PLA General Hospital · starts Sep 5, 2025
- A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related DiseaseNCT07068165 · Phase 2 / Phase 3 · Peking Union Medical College Hospital · starts Jul 7, 2025
- A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesNCT06978647 · Phase 1 · China Immunotech (Beijing) Biotechnology Co., Ltd. · starts May 19, 2025
- A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RDNCT07104058 · Not applicable · Luo Yaping · starts May 10, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Dec 8, 2025 | Open-label, uncontrolled, multicenter trial to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of inebilizumab in children from 2…UPLIZNA | Amgen | Closed |
| Jul 29, 2025 | A randomized, phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (sar444671) compared to placebo in adult participants…RILZABRUTINIB (SAR444671) | SANOFI-AVENTIS CANADA INC | Ongoing |
| Mar 9, 2023 | A phase 3, multicenter, randomized, doubleblind, placebo-controlled study to evaluate the efficacy and safety of obexelimab in patients with igg4-related…OBEXELIMAB (XMAB5871) | ZENAS BIOPHARMA (USA) LLC | Ongoing |
| Jul 20, 2020 | A phase 3, randomized, double-blind, multicenter, placebo-controlled study of inebilizumab efficacy and safety in igg4 related diseaseINEBILIZUMAB | Amgen | Ongoing |
| Apr 8, 2020 | An open label, two-arm, phase 2a study to evaluate the effect of rilzabrutinib (prn1008/sar444671) on safety and disease activity in patrticipants with…RILZABRUTINIB (PRN1008) | PRINCIPIA BIOPHARMA INC | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA